Key result
Correction updates funding statement for a meta-analysis on siRNA therapies for hypertriglyceridemia and mixed dyslipidemia.
Correction to funding disclosure leaves siRNA meta-analysis conclusions on hypertriglyceridemia unchanged; underscores need for transparent reporting in systematic reviews.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied hypertriglyceridemia and mixed dyslipidemia. small interfering RNA (siRNA) therapies was evaluated. This is a correction article updating the funding statement of a previously published systematic review and meta-analysis on siRNA therapies for hypertriglyceridemia and mixed dyslipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: